Zylox-Tonbridge Medical Technology Co., Ltd. Class H (HK:2190)
:2190
Top Page
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
(2190)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$27.00
▲(9.58% Upside)
Action:ReiteratedDate:11/22/25
Zylox-Tonbridge Medical Technology's strong revenue growth and profitability improvements are offset by significant cash flow challenges and a high valuation. Technical indicators suggest mixed momentum, contributing to a moderate overall stock score.
Positive Factors
Revenue Growth & Profitability Improvement
Sustained multi-year top-line expansion and a shift to positive net margins indicate durable product-market fit and scalable distribution. This growth supports reinvestment in R&D and commercial expansion, strengthening competitive positioning over the medium term.
Negative Factors
Weak Cash Flow Generation
Negative operating cash flow undermines the company’s ability to convert strong reported earnings into internally generated capital. Persistent cash conversion issues force dependence on external financing, constraining durable funding for growth and working capital needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Profitability Improvement
Sustained multi-year top-line expansion and a shift to positive net margins indicate durable product-market fit and scalable distribution. This growth supports reinvestment in R&D and commercial expansion, strengthening competitive positioning over the medium term.
Read all positive factors
Zylox-Tonbridge Medical Technology Co., Ltd. Class H (2190) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$8.30B
Dividend Yield0.48%
Average Volume (3M)743.29K
Price to Earnings (P/E)27.9
Beta (1Y)0.69
Revenue Growth35.01%
EPS Growth483.73%
CountryHK
Employees875
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.42
Shares Outstanding336,350,740
10 Day Avg. Volume433,268
30 Day Avg. Volume743,287
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.15
Price to Sales (P/S)4.57
P/FCF Ratio-207.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$32.00Price Target Upside29.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.98
Revenue Forecast (FY)HK$1.48B
Zylox-Tonbridge Medical Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Zylox-Tonbridge Medical Technology Co., Ltd. Class H (2190) is a leading player in the medical technology sector, specializing in the research, development, manufacturing, and distribution of advanced medical devices and solutions. The company foc...
How the Company Makes Money
Zylox-Tonbridge generates revenue primarily through the sale of its medical devices and diagnostic equipment to hospitals, clinics, and healthcare providers. The company operates on a business-to-business (B2B) model, where it sells its products d...
Zylox-Tonbridge Medical Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
85
Very Positive
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 898.46M | 782.48M | 527.75M | 334.09M | 177.91M | 27.63M |
| Gross Profit | 642.09M | 559.89M | 384.99M | 252.67M | 131.88M | 16.29M |
| EBITDA | 101.16M | 65.30M | -41.60M | -86.56M | -208.49M | -90.16M |
| Net Income | 152.59M | 100.26M | -78.73M | -113.56M | -199.69M | -100.47M |
Balance Sheet | ||||||
| Total Assets | 3.50B | 3.45B | 3.38B | 3.25B | 3.25B | 503.97M |
| Cash, Cash Equivalents and Short-Term Investments | 1.61B | 1.28B | 1.51B | 1.86B | 2.93B | 317.26M |
| Total Debt | 83.12M | 90.91M | 55.88M | 14.00M | 9.40M | 34.22M |
| Total Liabilities | 341.97M | 351.56M | 328.32M | 159.54M | 103.61M | 79.28M |
| Stockholders Equity | 3.15B | 3.10B | 3.05B | 3.09B | 3.14B | 424.69M |
Cash Flow | ||||||
| Free Cash Flow | 607.00K | -17.26M | -92.48M | -236.60M | -205.80M | -127.47M |
| Operating Cash Flow | 70.04M | 174.08M | 98.44M | -91.32M | -116.21M | -82.33M |
| Investing Cash Flow | -136.59M | -801.36M | -206.24M | -95.05M | -1.33B | -249.18M |
| Financing Cash Flow | -47.60M | -41.98M | -11.46M | -30.26M | 2.81B | 345.54M |
Zylox-Tonbridge Medical Technology Co., Ltd. Class H Technical Analysis
Positive
24.64
Price Trends
23.30
Positive
23.71
Positive
23.31
Positive
Market Momentum
0.34
Negative
58.90
Neutral
69.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2190, the sentiment is Positive. The current price of 24.64 is above the 20-day moving average (MA) of 22.44, above the 50-day MA of 23.30, and above the 200-day MA of 23.31, indicating a bullish trend. The MACD of 0.34 indicates Negative momentum. The RSI at 58.90 is Neutral, neither overbought nor oversold. The STOCH value of 69.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2190.
Zylox-Tonbridge Medical Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$7.11B | 17.31 | 11.91% | 1.26% | 25.18% | 55.79% | |
69 Neutral | HK$8.15B | 19.30 | 9.39% | 1.88% | 14.56% | 61.60% | |
69 Neutral | HK$6.42B | 31.02 | 11.84% | 1.50% | -5.18% | -9.69% | |
58 Neutral | HK$8.30B | 27.86 | 4.88% | 0.48% | 35.01% | 483.73% | |
57 Neutral | HK$7.82B | 36.52 | 1.98% | ― | 3.42% | -70.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$4.13B | -18.13 | -11.27% | ― | 29.25% | 9.02% |
* Healthcare Sector Average
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
24.12
7.73
47.21%
HK:9996
Peijia Medical Ltd.
6.16
1.06
20.78%
HK:1302
LifeTech Scientific Corporation
1.81
0.22
13.84%
HK:1789
AK Medical Holdings Ltd.
6.34
0.33
5.49%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
13.83
3.92
39.56%
HK:2172
MicroPort NeuroTech Limited
10.97
0.09
0.83%
Zylox-Tonbridge Medical Technology Co., Ltd. Class H Corporate Events
Zylox-Tonbridge to Acquire 49% Stake in Medical Tech Firm with Option to Take Full Control
Jan 15, 2026
Zylox-Tonbridge Medical Technology has agreed to acquire a 49% equity stake in an independent medical technology firm, referred to as the Target Company, from E-Med Solutions for approximately EUR18.375 million (about RMB149.41 million), with the ...
Zylox-Tonbridge Amends Articles Following Share Incentive Issuance
Dec 8, 2025
Zylox-Tonbridge Medical Technology Co., Ltd. announced amendments to its Articles of Association following the issuance of 13.95 million H Shares under its 2025 Share Incentive Scheme. This has resulted in an increase in the company’s regist...
Zylox-Tonbridge Announces RSU Grants Under 2025 Share Incentive Scheme
Oct 24, 2025
Zylox-Tonbridge Medical Technology Co., Ltd. has announced the grant of 13,950,000 restricted stock units (RSUs) to 44 selected participants as part of its 2025 Share Incentive Scheme. This initiative aims to align the interests of the companyR...
Zylox-Tonbridge Successfully Concludes 2025 EGM with All Resolutions Passed
Oct 24, 2025
Zylox-Tonbridge Medical Technology Co., Ltd. successfully held its 2025 First Extraordinary General Meeting on October 24, 2025, where all proposed resolutions were passed. The meeting saw significant shareholder participation, with specific resol...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.